Z Szallasi


Affiliation: Harvard University
Country: USA


  1. Klikovits T, Lohinai Z, Fabian K, Gyulai M, Szilasi M, Varga J, et al. New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study. Lung Cancer. 2018;126:139-148 pubmed publisher
    ..Central LADC is associated with early metastatic disease, bone involvement and, consequently, decreased survival. ..
  2. Póti A, Berta K, Xiao Y, Pipek O, Klus G, Ried T, et al. Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts. Br J Cancer. 2018;119:1392-1400 pubmed publisher
    ..Mutagenesis due to prolonged use of PARP inhibitors in cancer treatment is therefore not expected to contribute to the genetic evolution of resistance, generate significant immunogenic neoepitopes or induce secondary malignancies. ..
  3. Jósa V, Krzystanek M, Eklund A, Salamon F, Zarand A, Szallasi Z, et al. Relationship of postoperative thrombocytosis and survival of patients with colorectal cancer. Int J Surg. 2015;18:1-6 pubmed publisher
    ..Furthermore, the observation of postoperative thrombocytosis with significant worse outcome underlines the predictive power of elevated platelet count. ..
  4. Szikriszt B, Póti A, Pipek O, Krzystanek M, Kanu N, Molnar J, et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics. Genome Biol. 2016;17:99 pubmed publisher
    ..Our results suggest genetic reversion due to cisplatin-induced mutations as a distinct mechanism for developing resistance. ..